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Abstract. Hydroxyzine dihydrochloride (HDH), a piperazine H1-
receptor antagonist and antihistamine, is a rapid acting anxiolytic 
used principally as an anti-emetic. A sensitive, selective, and precise 
and accurate spectrophotometric method based on the formation of 
an ion-pair with orange II (ORG II) as ion-pair complexing agent 
was developed and validated for the determination of HDH in phar-
maceuticals. The chloroform-extractable ion-pair complex exhibited 
an absorption maximum at 480 nm. Optimization of different experi-
mental conditions is described. Beer’s law is obeyed in the range of 
1.5-15 µg mL-1 with an apparent molar absorptivity value of 2.07 × 
104 L mol-1 cm-1 and Sandell’s sensitivity value of 0.0216 µg cm-
2. The limit of detection (LOD) and limit of quantification (LOQ) 
are 0.14 and 0.41 µg mL-1, respectively. A Job’s plot of absorbance 
versus molar ratio of HDH to ORG II indicated (1:2) stoichiometric 
ratio. Within- and between-day relative standard deviations at three 
different concentration levels were < 3%. The developed method was 
successfully applied to commercial tablets. The results obtained were 
in good agreement with those obtained using the official method. 
No interference was encountered from co-formulated substances. 
Recoveries were 96-109 %.
Keywords: Spectrophotometry, hydroxyzine, orange II, pharmaceu-
ticals.
Resumen. El dihidrocloruro de hidroxicina (HDH), una piperazina 
antagonista del receptor H1 y un antihistamínico, es un ansiolítico de 
acción rápida usado principalmente como anti-emético. Se desarrolló 
y validó un método espectrofotométrico sensible, selectivo, preciso y 
exacto basado en la formación de un par iónico con naranja II (ORG 
II) como un agente complejante para la determinación de HDH en 
productos farmacéuticos. El par iónico extraído en cloroformo exhi-
bió un máximo de absorción a 480 nm. Se describió la optimización 
de las diferentes condiciones experimentales. La ley de Beer se obe-
deció en el intervalo de 1.5-15 µg mL-1 con un valor de absortividad 
molar aparente de 2.07 × 104 L mol-1 cm-1 y un valor de sensibilidad 
de Sandell de 0.0216 µg cm-2. El límite de detección (LD) y el límite 
de cuantificación (LC) son 0.14 y 0.41 µg mL-1, respectivamente. 
Una gráfica de Job de absorbancia versus relación molar de HDH y 
ORG II indicó una relación estequiométrica (1:2). Las desviaciones 
estándar relativas dentro y entre días, a tres diferentes niveles de 
concentración, fueron < 3%. El método desarrollado fue aplicado exi-
tosamente a tabletas comerciales. Los resultados obtenidos estuvieron 
en buena concordancia con los obtenidos con el método oficial. No se 
encontró ninguna interferencia de parte de las sustancias de la formu-
lación. Las recuperaciones fueron de 96-109 %.
Palabras clave: Espectrofotometría, hidroxicina, naranja II, produc-
tos farmacéuticos.
Introduction
Hydroxyzine dihydrochloride (HDH), chemically known as 
2-[2-[4-[(4-chlorophenyl)phenymethyl]-1-piperazinyl]ethoxy
]ethanol, dihydrochloride, is a piperazine H1-antagonist with 
sedative properties. It is widely used in the control of anxiety 
[1] and also used principally as an anti-emetic [2, 3].
A variety of analytical techniques such as high-perfor-
mance liquid chromatography [4-8], gas chromatography [9], 
thin layer chromatography [10], micellar liquid chromatog-
raphy [11], capillary zone electrophoresis [3], voltammetry 
[12], LC-MS [13], potentiometry [14, 15], gravimetry [16] and 
titrimetry [17-22] have been reported for the determination 
of HDH in biological fluids and pharmaceuticals. The offi-
cial USP method available for the assay of the drug in tablets 
employs a chromatographic system equipped with a UV-detec-
tor, where HDH can be detected at 232 nm [23].
In the literature, four visible spectrophotometric methods 
[18, 24-26] are found for the quantitative determination of HDH 
in pharmaceuticals. In the method reported by Basavaiah and 
Charan [18], to a fixed concentration of Hg(II)-diphenylcar-
bazone complex different amounts of drug were added and the 
decrease in the absorbance of Hg(II)-diphenylcarbazone com-
plex, consequent to the replacement of diphenylcarbazone of 
the complex by the chloride of the drug, was measured at 540 
nm and the method is applicable in the range 0-60 µg mL-1. 
Sane et al [24] have used 3 dyes for the determination of the 
drug content in pharmaceuticals. Kurzawa et al [25] employed 
the spectrophotometric procedure for HDH by using reinecke 
salt. One of the present authors has also reported a method 
based on the charge transfer complex formation reaction with 
chloranilic acid [26] in acetonitrile.
The reported visible spectrophotometric methods though 
seem simple, they are less sensitive [18, 26], some are criti-
cally dependent on pH [24] and the reaction products either 
require long time to form or less stable [25] (Table 1).
The present work describes a simple, sensitive and selec-
tive spectrophotometric method for the determination of HDH 
in pharmaceuticals. The method is based on the measurement 
of the red coloured chloroform extractable ion-pair complex 
formed between HDH and ORG II in H2SO4 medium. The 
HDH-ORG II ion-pair complex is highly stable and the ion-
pair formed and extracted in acid medium without requiring 
rigid pH control.
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Results and discussions
Ion-pair extractive spectrophotometry has gained great atten-
tion for the pharmaceutically important compounds [27-31]. 
Due to the sulfonate anionic group present in the dye, ORG II, 
there is a strong tendency to form the complex with the coun-
ter cations as ion-pair complex.
Hydroxyzine, as a positively charged amino compound in 
acid medium, forms chloroform extractable red colored ion-
pair complex with the anionic dye ORG II and the resulting 
red colored species shows an absorption maxima at 480 nm 
(Fig 1). The structures of the protonated HDH, ORG II and 
HDH-ORG II ion-pair complex are shown in scheme 1.
Table 1. Comparison of the performance characteristics of the proposed method with reported visible spectrophotometric methods.
Sí.
No.
Reagent/s used Methodology λmax (nm) Linear range 
(µg mL-1) 
(ε in L mol-1 
cm-1)
LOD (µg 
mL-1)
Remarks Ref
1 Hg(II)-
diphenylcarbazone
Decrease in the 
absorbance of Hg(II)-
diphenylcarbazone 
complex measured
540 0-60 
(6.62 × 103)
NA Less sensitive 18
2 Three dyes Measurement of 
absorbance of ion-pair 
complex
410 — NA Ion-pair formation 
and extraction entirely 
depends on pH
24
3 Reinecke salt Absorbance of 
hydroxyzine-
reineckate complex 
measured
525.5 30-525 
(1.27 × 105)
NA The procedure tedious 
and time consuming 
in which the drug is 
precipitated as Reinecke 
salt, filtered, dried at 
60 °C for 6 h and then 
dissolved in acetone 
before measuring the 
absorbance
25
4 Chloranilic acid-
acetonitrile, 
ammonia
Absorbance of charge-
transfer complex 
measured
535 25-150 
(1.37 × 103)
1.25 Less sensitive 26
5 ORG II-CHCl3 Absorbance of HDH-
ORG II ion-pair 
complex measured
480 1.5-15 
(2.07 × 104)
0.14 Highly sensitive, 
applicable for wide 
linear dynamic range, 
Highly stable coloured 
product
Present work
ε. Molar absorptivity; NA. Not available.
A
B
Fig. 1. Absorption spectra of: A. ion-pair complex (9.0 µg mL-1 
HDH); B. blank.
Scheme 1. Structures of i) HDH; ii) protonated HDH; iii) ORG II and 
iv) HDH-ORG II ion-pair complex.
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In order to establish optimum conditions necessary for 
rapid and quantitative formation of coloured product with 
maximum stability and sensitivity, control experiments were 
performed by measuring the absorbance at 480 nm by varying 
one and fixing the other parameters.
Method development: Optimization of 
experimental variables
Effect of concentration of sulphuric acid. Effect of H2SO4 
concentration of the aqueous solution on the formation and 
extraction of the HDH-ORG II ion-pair was studied by vary-
ing the concentration of the acid in the range 0.0333-0.333 M 
(1-5 mL of 2 M acid in a total volume of 30 mL) keeping all 
other variables constant (5 mL of 30 µg mL-1 HDH, 20 mL 
water and 5 mL dye solution), and it was found that maximum 
and constant absorbance readings were obtained in the range 
studied (fig 2), but the absence of H2SO4 resulted in lower 
absorbance. When the acid concentration of the aqueous phase 
was 0.0333 M, (1 mL of 2 M), blank showed negligible absor-
bance, but showed increasing trend with increasing concentra-
tion of the acid. So, 1 mL of 2 M H2SO4 in a total volume of 
30 mL (0.0333 M) was used throughout the investigation.
Effect of ORG II. The effect of ORG II concentration on the 
formation of ion-pair was investigated by varying the volume 
of dye solution, and using a fixed concentration of drug. The 
results revealed that the complex formation and its extraction 
were unaffected in the range of 2.0 to 10.0 mL of 0.1% ORG 
II solution. Hence, 5 mL of 0.1 % ORG II solution was fixed 
as optimum in a total volume of 30 mL of aqueous phase.
Effect of ratio of aqueous to organic phases. In order to 
obtain the maximum absorbance, 3 mL HDH solution (30 µg 
mL-1) and 1 mL of 2 M H2SO4 were diluted to 5, 10, 15, 20, 
25 and 30 mL with water before mixing with 5 mL of the dye 
solution and the ion-pair was extracted with 10 mL of CHCl3. 
The study revealed that, minimum blank absorbance and maxi-
mum complex absorbance values were obtained with clear 
separation of organic and aqueous layers when the volume of 
water in the aqueous phase was maintained at > 20 mL. Hence, 
an aqueous phase volume of 30 mL was used in all subsequent 
work.
Choice of organic solvent. It was found that the ion-pair com-
plex was readily and quantitatively extractable in chloroform. 
In chloroform reproducible and precise results were obtained. 
Therefore chloroform was used as extracting solvent.
Reaction time. After the addition of dye, the effect of standing 
time was studied in the time range 5-30 min before extraction. 
After a contact time of 5 min, measured absorbance of the 
complex after extraction into chloroform, showed almost con-
stant from 5-30 min. So a contact time of 5 min was adequate 
for the complex to form.
Effect of shaking time. The effect of the shaking time on the 
extraction of the HDH-ORG II ion-pair was studied. Shaking 
times ranging from 30 to 180 s produced no change in absor-
bance, by maintaining all other parameters constant. So a 30 
sec shaking time was fixed.
Number of extractions. To obtain a quantitative extraction 
of the HDH-ORG II ion-pair, under optimum conditions, the 
drug-dye ion-pair in the aqueous phase was extracted with 
three 10 mL portions of CHCl3 successively and absorbance 
was measured each time. After the second extraction, the 
absorbance of the organic layer was negligibly small. Hence, a 
single extraction with 10 mL of CHCl3 was used in subsequent 
work.
Equilibration time and stability of the coloured complexes. 
The organic and aqueous phases were clearly separated in 
less than 1 min. The drug-dye ion-pair complex was stable for 
more than 72 h at laboratory temperature (30 ± 2 °C).
Effect of order of addition of reactants. The sequence of 
order of addition of the reactants prior to extraction had small 
change in the absorbance values. So the order of addition of 
reactants should be in the described manner.
Study of the complexing ratio of the drug and dye. The 
complexing ratio of HDH and ORG II was examined by Job’s 
continuous variations method [32]. Aqueous HDH and dye 
solutions of 5.1 × 10-4 M each were mixed in various molar 
ratios (with a total volume of 6 mL). After adding 1 mL 
H2SO4, the total volume was diluted to 30 mL with water. 
The extraction was performed using 10 mL of CHCl3 and the 
absorbance was measured at 480 nm. The graph of the results 
obtained (fig. 3) gave a maximum at a molar ratio of Xmax = 
0.333 which indicated the formation of a 1:2 (HDH:ORG II) 
complex.
Fig. 2. Effect of sulphuric acid concentration on the absorbance of 
the drug-dye ion-pair complex obtained for 15 µg mL-1 HDH, 5 mL 
ORG II dye (0.1%), 30 mL aqueous phase and 10 mL CHCl3 (organic 
phase).
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Method Validation
Linearity, sensitivity, limits of detection and quantification. 
Calibration graph was constructed from six points covering 
the concentration range 1.5-15.0 µg mL-1. Regression analysis 
of the Beer’s law data indicated a linear relationship between 
absorbance and concentration, (Table 2) which is corroborated 
by high value (close to unity) of the correlation coefficient. A 
plot of log absorbance and log concentration, yielded straight 
line with slope equal to 1.002, further establishing the linear 
relation between the two variables. The calculated molar 
absorptivity and Sandell sensitivity [33] values are summa-
rized in Table 2. The limits of detection (LOD) and quantifica-
tion (LOQ) were calculated according to the ICH guidelines 
[34] using the formulae:
LOD = 3.3 S/b and LOQ = 10 S/b, (where S is the stan-
dard deviation of blank absorbance values, and b is the slope 
of the calibration plot). The values are also summarized in 
Table 2. The high value of ε and low value of Sandell sensi-
tivity and LOD indicate the high sensitivity of the proposed 
method.
Precision and accuracy. The assays described under “General 
Procedures” were repeated seven times within the day to deter-
mine the repeatability (intra-day precision) and five times on 
different days to determine the intermediate precision (inter-
day precision) of the method. These assays were performed 
for three levels of analyte. The results of this study are sum-
marized in Table 3. The percentage relative standard deviation 
(%RSD) values were ≤ 2.6% (intra-day) and ≤ 3% (inter-day) 
indicating high precision of the method. The accuracy of the 
method was determined by the percent mean deviation from 
known concentration, bias % = [(concentration found - known 
concentration) × 100 / known concentration]. Bias was calcu-
lated at each concentration and these results are also presented 
in Table 3. Percent relative error (%RE) values ≤ 2% demon-
strate the high accuracy of the proposed method.
Recovery study. To further assess the accuracy of the meth-
od, recovery experiments were performed by applying the 
standard-addition technique. The recovery was assessed by 
determining the agreement between the measured standard 
concentration and added known concentration to the sample. 
The test was done by spiking the pre-analyzed tablet powder 
with pure HDH at three different levels [50, 100 and 150 % of 
the content present in the tablet powder (taken)] and the total 
was found by the proposed method. Each test was repeated 
three times. In all the cases, the recovery percentage values 
ranged between 98.33 and 104.4 with standard deviation in the 
range 1.42-2.98%. Closeness of the results to 100 % showed 
the fairly good accuracy of the method. The results are shown 
in Table 4.
Selectivity. A systematic study was performed to determine the 
effect of matrix on the performance of the method by analyz-
ing the placebo blank and synthetic mixture containing HDH. 
A placebo blank of the composition: starch (10 mg), acacia (15 
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Fig. 3. Job’s method of equimolar solutions for the HDH-ORG II 
complex in CHCl3.
Table 2. Sensitivity and regression parameters.
Parameter Value
λmax, nm 480
Color stability >72 h
Linear range, µg mL-1 1.5-15
Molar absorptivity(ε), L mol-1 cm-1 2.07 × 104
Sandell sensitivity*, µg cm-2 0.0216
Limit of detection (LOD), µg mL-1 0.14
Limit of quantification (LOQ), µg mL-1 0.41
Regression equation, Y**
Intercept (a) -0.0260
Slope (b) 0.05
Standard deviation of a (Sa) 0.013
Standard deviation of b (Sb) 0.0014
Variance (Sa2) 1.69 × 10-4
Regression coefficient (r) 0.9990
*Limit of determination as the weight in µg per mL of solution, 
which corresponds to an absorbance of A = 0.001 measured in a 
cuvette of cross-sectional area 1 cm2 and l = 1 cm. **Y = a + bX, 
where Y is the absorbance, X is concentration in µg mL-1, a is 
intercept, b is slope.
Table 3. Evaluation of intra-day and inter-day accuracy and precision.
HDH taken, 
µg mL-1
Intra-day accuracy 
and precision 
(n = 7)
Inter-day accuracy 
and precision 
(n = 5)
HDH 
found*, 
µg mL-1
%RE %RSD HDH 
found*, 
µg mL-1
%RE %RSD
3.0 3.06 2.0 2.60 2.96 1.33 2.99
9.0 8.85 1.67 1.40 9.08 0.89 1.86
15.0 15.06 0.40 1.70 15.16 1.07 2.36
%RE. Percent relative error, SD. Standard deviation, %RSD. relative 
standard deviation.
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mg), hydroxyl cellulose (10 mg), sodium citrate (10 mg), talc 
(20 mg), magnesium stearate (15 mg) and sodium alginate (10 
mg) was obtained and its solution was prepared as described 
under ‘tablets’, and then subjected to analysis. The absorbance 
of the placebo solution almost equal to the absorbance of the 
blank which revealed no interference from the above sub-
stances. To assess the role of the inactive ingredients on the 
assay of HDH, a synthetic mixture was separately prepared by 
adding 10 mg of HDH to the placebo mentioned above. The 
drug was extracted and solution prepared as described under 
the general procedure for tablets. The solution after appropri-
ate dilution was analyzed following the recommended proce-
dure. The absorbance of the coloured product resulting from 
the extract containing 10 µg mL-1 HDH was nearly the same 
as that obtained for pure HDH solution of identical concentra-
tion. This unequivocally demonstrated the non-interference of 
the inactive ingredients in the assay of HDH. Further, the slope 
of the calibration plot prepared from the synthetic mixture 
solution was about the same as that prepared from pure drug 
solution.
Robustness and ruggedness. The robustness of the method 
was evaluated by making small incremental changes in vol-
ume of H2SO4 and contact time and the effect of the changes 
was studied on the absorbance of the coloured systems. The 
changes had negligible influence on the results as revealed by 
small intermediate precision values expressed as % RSD (≤ 
1.68%).
Method ruggedness was demonstrated by having the 
analysis done by four analysts, and also by a single analyst 
performing analysis on four different instruments in the same 
laboratory. Intermediate precision values (%RSD) in both 
instances were in the range 1.78-3.58 % indicating acceptable 
ruggedness. The results are presented in Table 5.
Application
The proposed method was applied for the quantification of 
HDH in commercial tablets. The results were compared with 
these obtained by the official US Pharmacopoeial method [23]. 
Statistical analysis of the results did not detect any significant 
difference in performance between the proposed method and 
reference method with respect to accuracy and precision as 
revealed by the Students t-value and variance ratio F-value 
[35]. The results of assay are given in Table 6.
Conclusion
The ion-pair extractive spectrophotometric method for the 
determination of HDH in bulk drug and tablets was developed 
and validated for matrix effects, selectivity, linearity, sensi-
tivity, precision and accuracy. The sensitivity offered by the 
proposed method surpasses that of the existing spectropho-
tometric methods in terms of linear range and quantification 
limits. The method is quite selective as the drug contains basic 
moiety which preferentially interacts with orange II, and the 
drug-dye ion-pair is extracted into the organic solvent before 
measurement. Simplicity of pretreatment and measurement, 
and use of non-rigid experimental conditions could make the 
proposed method as effective tool to analyze accurately and 
precisely HDH in tablets using simple instrumentation and 
low-cost materials.
Experimental
Apparatus. A Systronics model 106 digital spectrophotometer 
with 1 cm path length quartz cells was used for absorbance 
measurements.
Chromatographic analyses were carried out using Alliance 
Waters HPLC system equipped with Alliances 2657 series low 
pressure quaternary pump, a programmable variable wave-
length UV-visible detector, Waters 2996 photodiode array 
detector and auto sampler. Data were collected and processed 
using Waters Empower 2.0 software.
Chemicals and reagents. All chemicals used were of analyti-
cal reagent grade. Chloroform (spectroscopic grade) was pur-
chased from Merck, Mumbai, India. Distilled water was used 
throughout the investigation.
Table 4. Results of recovery study via standard-addition method.
Tablets 
studied
HDH in 
tablet, µg 
mL-1
Pure HDH 
added, µg 
mL-1
Total HDH 
found ± 
SD*, µg 
mL-1
% HDH 
recovered
Atarax 25 6.01 
6.01 
6.01
3.0 
6.0 
9.0
9.08 ± 0.18 
12.21 ± 0.23 
15.41 ± 0.42
102.3 
103.3 
104.4
Atarax 10 6.0 
6.0 
6.0
3.0 
6.0 
9.0
8.95 ± 0.22 
11.99 ± 0.17 
15.15 ± 0.24
98.33 
99.83 
101.7
*Mean value of three determinations.
Table 5. Method robustness and ruggedness expressed as 
intermediate precision (% RSD).
HDH 
taken, 
µg mL-1
Robustness Ruggedness
Parameters altered Inter-analysts 
(%RSD), 
(n = 4)
Inter-
instruments 
(%RSD), 
(n = 4)
Volume 
of H2SO4*
Reaction 
time**
3 1.68 0.96 2.64 3.58
9 0.84 1.03 1.78 2.86
15 0.78 0.93 2.36 3.14
*The volumes of H2SO4 used were 0.8, 1.0 and 1.2 mL.
**The reaction times were 4, 5 and 6 min.
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Sulphuric acid (2 M): Concentrated acid (S.D. Fine Chem, 
Mumbai, India, sp. gr. 1.84) was appropriately diluted with 
water to get 2 M.
Sodium hydroxide (2 M): Prepared by dissolving 8 g of 
the pure NaOH (Merck, Mumbai, India) in water and diluting 
to 100 mL with water.
Orange II (ORG II), (0.1 %): Accurately weighed 500 mg 
of the dye (S.D. Fine Chem, Mumbai, India) was dissolved in 
water with the aid of heat, filtered through Whatman No.42 
filter paper and diluted to 500 mL with water.
Preparation of standard drug solution (proposed method). 
Pharmaceutical grade HDH was procured from UCB Pharma 
Ltd, Mumbai, India, as a gift, and was used as received. A 
stock standard solution of HDH (750 µg mL-1) was prepared 
by dissolving accurately weighed 75 mg of pure drug in water 
and diluting to the mark in a 100 mL graduated flask. The 
solution was diluted stepwise with water to get 30 µg mL-1 
HDH solution and used.
Preparation of sample (Reference HPLC method). Pure 
HDH solution. A 100 µg mL-1 standard HDH solution was 
prepared in methanol by dissolving accurately weighed 10 mg 
of pure drug in a 100 mL volumetric flask. The stock solution 
was diluted to 6 and 9 µg mL-1 with methanol to get working 
solutions.
Tablet. Atarax 25 and Atarax 10 (UCB Pharma Ltd, Mumbai, 
India)-both tablets, were used in the investigation.
Twenty tablets were accurately weighed, finely pulver-
ized and mixed using a mortar and pestle. An amount of tablet 
powder equivalent to 10 mg HDH was weighed and transferred 
into a 100 mL volumetric flask, 50 mL of methanol was added 
and was sonicated for 20 min in an ultrasonic bath to complete 
dissolution of the HDH, and the mixture was then diluted to 
the mark with methanol, mixed well and filtered. The obtained 
100 µg mL-1 solution was diluted with methanol to get 6 and 9 
µg mL-1 HDH.
Chromatographic conditions. The analysis was carried out 
on a chromatopack column (250 mm × 4.6 mm i.d., 5 µm par-
ticle size). A solution containing a mixture of methanol and 
monobasic potassium phosphate (50:50) was used as a mobile 
phase. The flow rate was 2 mL min-1, the detector wavelength 
was set at 232 nm and the injection volume was 20 µL.
General procedures for pure drug. Proposed method. 
Varying volumes, 0.5, 1.0, 1.5, … 5.0 mL; of standard HDH 
solution (30 µg mL-1 equivalent to 1.5-15 µg mL-1 HDH) 
were transferred into a series of 125 mL separating funnels and 
the total volume was brought to 25 mL by adding water. Then, 
to each funnel were added 1 mL of 2 M H2SO4 and 5 mL of 
0.1 % ORG II dye solution. Content was mixed well and kept 
aside for 5 min. The drug-dye ion-pair was next extracted with 
10 mL of chloroform by shaking for 30 sec and the layers were 
allowed to separate. The organic layer was then passed over 
anhydrous sodium sulphate and the absorbance was measured 
at 480 nm against the reagent blank.
A standard graph was prepared by plotting the absorbance 
vs drug concentration, and the concentration of the unknown 
was read from the calibration graph or computed from the 
regression equation derived using the absorbance-concentra-
tion data.
Reference method
An aliquot of a 20 µL sample solution (6 or 9 µg mL-1) was 
injected (in triplicate) and eluted with the mobile phase under 
the described chromatographic condition. The average peak 
area was calculated for each concentration.
Assay procedures for tablets. Proposed method. Twenty 
tablets were weighed and powdered. An accurate amount of 
the powder equivalent to 30 mg of HDH was transferred into 
a 100 mL calibrated flask and 70 mL of water was added. The 
mixture was shaken for 20 min and, the volume was brought 
up to the mark with water. The solution was then filtered 
through Whatman No. 42 filter paper. The first 10 mL por-
tion of the filtrate was discarded and 10 mL of the filtrate was 
diluted to 100 mL to get a working HDH solution of 30 µg 
mL-1 and a suitable aliquot (say 3 mL) was used for assay fol-
lowing the procedure described above.
Reference method. An aliquot of 20 µL of tablet extract (100 
µg mL-1 HDH) prepared above was injected (triplicate) and 
eluted with the mobile phase under the reported chromato-
graphic conditions. By means of the average peak area, the 
quantity of HDH was calculated by using the following for-
mula:
 mg HDH = LC/D ru/rs
where L is the labeled quantity, in mg, of hydroxyzine hydro-
chloride in each tablet; D is the concentration, in μg mL-1 of 
Table 6. Results of analysis of tablets by the proposed method and 
statistical comparison of the results with the reference method.
Tablet 
brand 
nameψ
HDH 
taken
HDH found ± SD* Student’s 
t-value
Variance 
F-valueReference 
method
Proposed 
method
Atarax 25a 6.0 
9.0
6.07 ± 0.08 
9.05 ± 0.18
5.91 ± 0.16 
9.04 ± 0.15
2.11 
0.10
4.00 
1.44
Atarax 10a 6.0 
9.0
5.99 ± 0.05 
8.98 ± 0.12
6.03 ± 0.08 
8.97 ± 0.23
0.97 
0.10
2.56 
3.67
*Mean value of 5 determinations.
(Tabulated t-value at the 95 % confidence level and for four degrees 
of freedom is 2.77).
(Tabulated F-value at the 95 % confidence level and for four degrees 
of freedom is 6.39).
ψMarketed by: aUCB Pharma Ltd, Mumbai, India.
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hydroxyzine hydrochloride in the assay preparation on the 
basis of the labeled quantity in each tablet and the extent of 
dilution; C is the concentration, in μg mL-1, of pure HDH 
solution; and ru and rs are the average peak areas obtained 
from the tablet and pure drug solution, respectively.
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